Indoleamine 2,3-dioxygenase 2 mRNA (IDO2 mRNA) (IDO2 mRNA)

Indoleamine 2,3-dioxygenase 2 (IDO2) mRNA is the transcript encoding the IDO2 enzyme, a paralog of the more widely studied IDO1 (UniProt Q6ZQW0). Like IDO1, IDO2 is involved in the kynurenine pathway, where it catalyzes the oxidative cleavage of the essential amino acid L-tryptophan into N-formylkynurenine (NCBI Gene 169355). This process leads to the depletion of tryptophan and the accumulation of kynurenines in the microenvironment, which suppresses T-cell activity and promotes immune tolerance (PubMed PMID: 21835287). In the context of oncology, IDO2 is often overexpressed in various tumors, such as pancreatic and colon cancers, contributing to immune evasion (PubMed PMID: 25634305). Targeting IDO2 at the mRNA level using technologies like siRNA or antisense oligonucleotides aims to silence the gene's expression, thereby reducing the immunosuppressive environment and enhancing the efficacy of immunotherapies. While IDO2 has lower catalytic efficiency than IDO1, its distinct expression pattern and role in specific inflammatory and oncogenic pathways make it a unique therapeutic target (PubMed PMID: 29109145).

Other names

INDOL1 mRNAIndoleamine 2,3-dioxygenase-like protein 1 mRNAIDO-2 mRNA

The primary mechanism for targeting IDO2 mRNA involves RNA interference (RNAi) or antisense oligonucleotide (ASO) technology to induce sequence-specific degradation of the transcript, thereby preventing the translation of the IDO2 enzyme and reducing immunosuppressive tryptophan catabolism (PubMed PMID: 29109145).